Lupin's AMD Treatment Biosimilar Ranluspec Secures Final EMA Marketing Authorization in Europe
Ranibizumab Biosimilar Established in the European Market
Lupin, an Indian pharmaceutical company, has secured final marketing authorization from the European Medicines Agency (EMA) for Ranluspec, its biosimilar for the treatment of age‑related macular degeneration (AMD). The approval follows a Positive Opinion issued by the Committee for Medicinal Products for Human Use (CHMP) on 11 December 2025 and was formally granted on 10 February 2026. Ranluspec demonstrated equivalence to the reference product Lucentis and met the agency’s stringent quality standards. This European approval, together with the Interchangeable Biosimilar designation granted by the U.S. Food and Drug Administration (FDA) on 2 June 2026, is expected to serve as a catalyst for Lupin’s global market expansion.
Vision‑Improving Mechanism via VEGF Inhibition
Ranluspec’s active ingredient, ranibizumab, is a monoclonal antibody fragment that targets vascular endothelial growth factor‑A (VEGF‑A), a protein that drives abnormal ocular neovascularization. By inhibiting VEGF‑A, the drug reduces macular edema, limits fluid leakage, and preserves visual acuity. It is indicated for a broad range of retinal disorders, including neovascular (wet) age‑related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). Clinical data have confirmed comparable efficacy and safety to the reference product, enabling a seamless substitution.
Securing European Distribution through Partnership with Sandoz
Lupin has entered a strategic partnership with Sandoz, a global specialist in biosimilars, to reinforce its sales footprint across Europe. The European anti‑VEGF ophthalmology market was valued at approximately $7.86 billion in 2025 and is expected to grow further as the population ages. Leveraging Sandoz’s extensive local sales network, Lupin aims to penetrate the market segment historically dominated by Lucentis and capture share in a short timeframe. Under a licensing agreement, the parties will hold exclusive distribution rights, generate synergistic benefits, and intensify localized medical marketing efforts.
Market Diversification and Future Commercialization Challenges
While the initial regulatory hurdle for European entry has been cleared, each country’s reimbursement listing and health technology assessment (HTA) processes remain to be navigated. In Europe, price negotiations with national health authorities are a decisive factor for early market share acquisition. Nevertheless, Ranluspec can incrementally increase its share by offering proven clinical benefit at a cost‑effective price relative to the reference product. As patents on incumbent therapies expire, Ranluspec is poised to become a cost‑saving therapeutic option for patients and healthcare budgets.
The EMA approval of Ranluspec signals entry into the commercialization phase in the European anti‑VEGF ophthalmology market, which was valued at approximately $7.86 billion in 2025, and positions the biosimilar as a substitute for the reference product Lucentis. Lupin and its partner Sandoz are expected to leverage their established sales infrastructure to rapidly capture Novartis’s incumbent market share through a price‑advantage strategy. In a retinal disease landscape populated by strong competitors such as Eylea and Vabysmo, the introduction of Ranluspec can substantially alleviate the financial burden on national health systems. Following the U.S. interchangeable designation, this European authorization demonstrates successive clearance of major regulatory hurdles and will serve as a positive lever for future out‑licensing agreements in other regions. Over the long term, the product will enable proactive defense against additional entrants, generate stable royalty streams, and expand Lupin’s capacity for further research and development investment, creating a virtuous cycle.
Source: EMA (ema)